Renal and bone effects risk minimisation material: Tenofovir disoproxil (Glenmark) for children and adolescents with HIV-1

This brochure provides important advice on the management of potential renal and bone effects of tenofovir disoproxil in HIV-1 infected children and adolescents aged 2 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.


electronic Medicines compendium